【摘要】 目的探讨阿尔茨海默病(AD)患者接受多奈哌齐治疗前后血浆β淀粉样蛋白-42(Aβ-42)水平的变化特点。方法选择2012年10月~2015年10月AD患者(50~80岁)55名,所有患者给予多奈哌齐治疗24周,检测每例患者治疗前后的智力情况及Aβ-42水平;另外,选择同年龄段55例智力正常的人为对照,并检测Aβ-42水平。结果治疗前AD患者血浆Aβ-42水平明显高于治疗后,并且明显高正常对照组,差异有统计学意义(P<0.01)。结论多奈哌齐对于AD有一定治疗作用,血浆Aβ-42水平可能作为反映老年期抑郁症患者病情和疗效的一项生物学指标。更多还原

【Abstract】 Objective To explore the characteristic of Plasma protein β amyloid protein 42(Aβ-42) Levels after donepezil treatment on Alzheimer’s Patients. Methods 55 cases of Patients with AD aging from 50~80 years old, from October 2012 to October 2015 were selected. Then each patient’s intelligence and Aβ-42 level were detected before and after the treatment with donepezil for 24 weeks. In addition, 55 people with normal intelligence in the same age group were chosen as control group,and the Aβ-42 level in each of them was also detected. Results All of AD patients before treatment Aβ-42 levels were significantly higher than after treatment, and which were significantly higher than normal control group, the differences were significant(P <0.01).Conclusions Donepezil has the function on treating AD,Plasma Aβ-42 Levels can become the objective biology target of reflection the condition and the treatment result of Alzheimer’s Patients.更多还原